title: Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
abstract: We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies. Eighty-six H. pylori-positive gastric ulcer patients were assigned randomly to one of seven groups: I, omeprazole 20 mg (n = 9); II, lansoprazole (LPZ) 30 mg (n = 16); III, LPZ 30 mg plus plaunotol 480 mg (n = 13); IV, LPZ 30 mg plus ecabet sodium 2 g (n = 11); V, LPZ 30 mg plus clarithromycin 600 mg (the first 2 weeks; n = 11); VI, LPZ 30 mg plus plaunotol 480 mg plus clarithromycin 600 mg (the first 2 weeks; n = 13); and VII, LPZ 30 mg plus ecabet sodium 2 g plus amoxicillin 1,500 mg (the first 2 weeks; n = 13). All therapy was for 8 weeks except where otherwise noted. H. pylori eradication rates as diagnosed by culture, histology, urease test, and [13C]urea breath test 4 weeks after stopping therapy were 0, 0, 8, 45, 6, 46, and 62%, respectively, in groups I-VII. No patient achieving H. pylori eradication suffered recurrence. The combination therapies with proton pump inhibitors in addition to antibiotics and antiulcer agents are safe and effective in H. pylori eradication.
authors.affiliation: Department of Internal Medicine IV, Hyogo College of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Fukuda
authors.forename: I
authors.initials: I
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Okui
authors.forename: Y
authors.initials: Y
authors.lastname: Tonokatsu
authors.forename: T
authors.initials: T
authors.lastname: Shimoyama
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage; D004224:Diterpenes / Q000008:administration & dosage; D005233:Fatty Alcohols / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D010406:Penicillins / Q000008:administration & dosage; D054328:Proton Pump Inhibitors; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D005233:Fatty Alcohols; D010406:Penicillins; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C061681:ecabet; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole; C047686:plaunotol